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Background: Chronic thoracic pain after cardiac surgery is prevalent (11 to 56%) and may affect patients’ physical
and mental health status. Despite its favorable pharmacokinetic and pharmacodynamic properties, high doses of
remifentanil administered during surgery are reported to cause acute postoperative pain and increased requirements
for analgesics. Recently, an association between remifentanil use and the incidence of chronic thoracic pain in the long
term was also reported. Our objective is to investigate the influence of the intraoperative remifentanil on chronic
postoperative pain in a prospective randomized controlled trial.
Methods/design: In this prospective, randomized, single-blind clinical trial, all patients (N =126) between 18 and
85 years undergoing cardiac surgery via sternotomy receive a continuous infusion of propofol together with intermittent
intravenous fentanyl at predetermined times perioperatively. Patients are randomized to receive either an additional
continuous infusion of remifentanil (0.15 μg−1kgIBW−1 min−1) or additional fentanyl (200 to 500 μg) as needed during
surgery.
The primary end point is the prevalence of chronic thoracic pain 12 months after surgery. Secondary end points include
acute postoperative pain; postoperative analgesic use; chronic thoracic pain 3 and 6 months after surgery; quality of life
(SF-12) at 3, 6 and 12 months after surgery; work productivity; and use of health care. In addition, thermal detection and
pain thresholds are measured preoperatively, 3 days after surgery and 12 months after surgery using quantitative sensory
testing (QST). Finally, the influence of several genetic variances on the different outcomes will be measured.
Discussion: Chronic thoracic pain is prevalent after cardiac surgery, and research is needed to minimize the risk of
chronic persistent postoperative pain, which is an invalidating, long-term complication of surgery. The objective of this
trial is to determine the influence of perioperative remifentanil on long-term pain outcomes for cardiac patients in a
prospective randomized trial. The results may be used to optimize perioperative analgesia techniques and, thereby,
improve quality of life after cardiac surgery.
Trial registration: Clinicaltrials.gov NCT02031016 on 13 December 2013.
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Remifentanil is a pain-relieving drug frequently used
during surgery due to its favorable pharmacokinetic and
pharmacodynamic properties. It is characterized by rapid
onset, predictable rapid recovery profile and dosing reli-
ability [1]. Its use is associated with a shorter length of
hospital stay and duration of mechanical ventilation after
cardiac surgery and a cardioprotective effect in coronary
artery bypass graft (CABG) surgery patients [2,3]. On
the other hand, high doses of remifentanil administered
during surgery have been reported to cause acute postop-
erative pain and opioid-induced hyperalgesia [4]. Acute
postoperative pain, in turn, is a major risk factor for the
development of chronic pain [5-7]. Studies report inci-
dences of chronic thoracic pain after cardiac surgery via
sternotomy varying from 11% to 56%, depending on the
definition and the study population [8-12]. These pa-
tients reported significantly lower physical and mental
health status compared to patients without chronic
thoracic pain [8,11,13,14].
Little is known about a possible association between
the intraoperative use of remifentanil and the develop-
ment of chronic pain. A dose-dependent relationship
was shown in 90 cardiac patients one year after surgery
[15]. Also a randomized study designed to evaluate allo-
dynia after thoracotomy and the occurrence of chronic
thoracic pain suggested that there might be an associ-
ation between the use of high dose remifentanil and in-
creased prevalence of chronic thoracic pain [16]. More
recently, a retrospective study found that the combin-
ation of remifentanil and sevoflurane was less favorable
in terms of chronic pain compared to a propofol and
remifentanil combination. Patients with chronic pain
had received a significantly higher dose of remifentanil,
but significance was not reached in multivariate ana-
lysis [17].
In our hospital, about 60% of cardiac surgery patients
receive remifentanil next to fentanyl intraoperatively, de-
pending on the anesthetist’s preference [15]. We wonder
whether the possible development of hyperalgesia and
chronic thoracic pain, with the negative impact on qual-
ity of life and cost efficacy, carries the risk of overcoming
the advantages of remifentanil.
So far, however, no prospective randomized con-
trolled trials designed to evaluate the influence of in-
traoperative remifentanil on the incidence of chronic
thoracic pain are available. The current prospective
randomized trial is designed to investigate the influ-
ence of perioperative additional remifentanil or add-
itional fentanyl on the development of chronic thoracic
pain at 3, 6 and 12 months after surgery. In addition,
changes in thermal detection thresholds and pain
thresholds and the influence of genetic variances will
be investigated.Methods/design
Study design
This study is a prospective, randomized, single-blind
clinical trial carried out in the St. Antonius Hospital,
Nieuwegein, the Netherlands (Figure 1). The study
population consists of adult cardiac patients undergoing
elective coronary artery bypass (CABG) surgery and/or
valve replacement surgery via sternotomy. Patients are
blinded for treatment and are randomly assigned to the
remifentanil or fentanyl group.
The study was approved by the local Ethics Committee
of this hospital (Verenigde Commissies Mensgebonden
Onderzoek (VCMO) R13.013). The study was registered
on the Clinical Trials register on 13 December 2013
(ClinicalTrials.gov number NCT02031016). The research
coordinator will obtain written informed consent from
each participant.
Eligibility
The following inclusion criteria are being applied: (1) pa-
tients undergoing cardiac surgery via sternotomy (a
CABG and/or valve replacement); and (2) age between
18 and 85 years; (3) weight between 45 and 140 kg. Ex-
clusion criteria are: (1) pregnancy or breastfeeding; (2)
language barrier; (3) history of drug abuse; (4) neuro-
logic condition such as peripheral neuropathy and fibro-
myalgia; (5) known remifentanil, fentanyl, morphine or
paracetamol allergy; (6) a body mass index (BMI) above
35 kg/m2 (7) prior cardiac surgery (re-operations); and
(8) patients with chronic pain conditions.
Interventions
Intraoperative analgesic protocol
Anesthesia will be induced with midazolam (2.5 to
5.0 mg) followed by a propofol bolus (1 to 2 mg/kg), fen-
tanyl (250 to 500 ug) and pancuronium (0.05-2 mg/kg).
After tracheal intubation, patients will be ventilated to
normocapnia with oxygen enriched air (50 to 100% oxy-
gen). No nitrous oxide will be used. Sevoflurane will be
used as needed. Both groups receive a continuous infu-
sion of propofol (starting dose 200 to 300 mg/hour) and
intermittent intravenous fentanyl at predetermined times
(that is, before incision, at sternotomy, at aorta cannula-
tion and at opening of the pericardium).
Patients in the remifentanil group will receive a con-
tinuous infusion of remifentanil (starting infusion dose
0.15 ug/kg ideal body weight (IBW)/min) on top of this
propofol-fentanyl anesthetic regimen. Patients in the
fentanyl group will receive additional boluses of fentanyl
200 to 500 μg as needed instead of the remifentanil
infusion.
Patients in both groups will receive 5 to 10 mg of
intravenous morphine 30 minutes before the anticipated
end of surgery. After surgery, patients will either go to
Figure 1 Flowchart of study outline.
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Care Unit (PACU).
Quantitative sensory testing
One day before surgery, three days after surgery and one
year after surgery quantitative sensory testing (QST) will
be performed. Cold and warm detection thresholds and
pain thresholds will be measured, using the ‘method of
limits’ with the Thermal Sensory Analyzer (TSA) II 2001
(Medoc Advanced Medical Systems, U.S.) [18,19]. The
threshold values will be corrected for age, gender and re-
action time. Before the first test session, patients will be
asked to practice testing at least twice. A test-retest vari-
ability of less than 20% is required before formal pain
testing begins. The TSA II has been used extensively to
determine warm/cold detection limits and warm/cold
pain thresholds.
Postoperative treatment
Patients in both groups will receive the same postopera-
tive treatment. In both the ICU and the PACU, a pain
management protocol is in place as part of standard
care, consisting of a continuous infusion of morphine
(starting dose of 2 mg/hour), which is adapted depend-
ing on Numerical Rating Scale (NRS) pain scores, as well
as paracetamol four times a day (1 g oral/intravenous)
[20]. Any perioperative fentanyl or remifentanil is dis-
continued at arrival at the ICU or PACU. NRS scoresare assessed three times a day and administered medica-
tion is registered as part of standard care. On the general
postoperative wards, the pain protocol consists of 2.5 to
10 mg morphine (oral/intravenous) on demand and
paracetamol four times a day (1 g oral).
Follow-up
After discharge from the hospital, patients will be asked
to complete questionnaires 3, 6 and 12 months after sur-
gery. This questionnaire contains questions about pain
(perception, location, intensity) based on the Brief Pain
Inventory [21] and was described previously [5]. In
addition, quality of life (QoL) is measured with the short
form (SF)-12 health status instrument, and work prod-
uctivity and use of health care resources are measured.
One year after cardiac surgery, pain thresholds are mea-
sured, using the same QST protocol.
Primary end point and secondary end points
The primary end point is the percentage of patients with
chronic thoracic pain (NRS >0) one year after cardiac
surgery.
Secondary end points are mean daily acute postopera-
tive NRS scores (0 to 10) and analgesic consumption until
discharge from the hospital. Also chronic pain (NRS),
Quality of Life, analgesic consumption, work productivity,
and use of health care 3, 6 and 12 months after surgery
are assessed. In addition, warm/cold detection and pain
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(baseline)) using quantitative sensory testing (QST) are
considered. The length of ICU, PACU and hospital stay
will be calculated.
In addition to primary and secondary endpoints, an
exploratory screening of different genes in this popula-
tion will be investigated. The possible influence of differ-
ent genetic variances that are involved in pain sensitivity
(for example, GTP-cyclohydrolase 1 (GCH-1), WDFY family
member 4 (WDFY4), Zinc Finger gene Family (ZNF), Mela-
nocortin 1 Receptor (MC1R)) and the pharmacokinetics
and pharmacodynamics of opiates (for example, glucur-
onosyl transferase (UGT), Multidrug Resistance-associated
Protein (MRP), mu-opioid receptor gene 1 (OPRM1),
Catechol-O-methyltransferase (COMT)) will be explored.
Data analysis
Statistical analyses will be done with The SPSS statistical
package (version 22.0 for Windows; SPSS, Chicago, IL).
Patient demographics, baseline characteristics and clin-
ical observations are compared between patients re-
ceiving remifentanil versus fentanyl during cardiac
surgery. Nonparametric data will be expressed as me-
dian (range) and analyzed by chi-square. Parametric
data will be expressed as mean ± SD and analyzed by
Student’s t-tests or ranks tests.
The effect of intraoperative use of remifentanil on
chronic pain one year after cardiac surgery is analyzed
using univariate logistic regression analysis. If baseline
characteristics are not balanced, multivariable tech-
niques will be applied. To evaluate the effect of remifen-
tanil versus fentanyl during cardiac surgery on pain
thresholds, paired t-tests will be used.
To estimate the effect of the genotype on the outcome
variables, each gene is examined to determine the appro-
priate model. The gene variants will be coded based on
the observed distribution. The outcome parameters are
compared between genotypes by a linear mixed model
analysis based on the maximum likelihood ratio with the
patient genotype status as fixed factors and the time
point of outcome parameters as repeated measurement.
Sample size calculations
In a previous study of 90 patients on chronic thoracic
pain after cardiac surgery, 15 of the 52 patients who re-
ceived remifentanil developed chronic thoracic pain
(29%) versus 3 of the 38 patients who did not receive
remifentanil (8%); resulting in an odds ratio of 4.7 [15].
Rounding numbers, the sample size calculation is
made on the assumption that in this prospective study,
approximately 30% of the patients receiving remifentanil
will develop chronic thoracic pain and that approxi-
mately 10% of the patients receiving fentanyl will de-
velop chronic thoracic pain.The sample size is calculated with a power of 0.80 and
an alpha of 0.05; two sided. A total number of 117 pa-
tients are needed. According to previous reports, mortal-
ity thirty days after cardiac surgery is approximately 2 to
13.3% [22,23]. In a previous study, 8.4% died within one
year after surgery [15]. Therefore, the total number of
patients needed in this trial is 117 * 1.08 = 126; 63 pa-
tients in each arm.
Discussion
This is the first randomized trial that prospectively eval-
uates the influence of intraoperative remifentanil on the
incidence of chronic thoracic pain. Studies in healthy
volunteers indicate that remifentanil increases the occur-
rence of secondary hyperalgesia in experimental pain
models [24-28]. Other studies have described higher
pain levels or analgesic requirements in the acute phase
after surgery upon intraoperative use of remifentanil
[4,29,30]. The clinical long-term relevance of these
mostly short-term increases in pain scores, analgesic re-
quirements or secondary hyperalgesia is unknown.
The putative biological mechanism by which remifen-
tanil would cause chronic pain is unclear. Opioid-
induced hyperalgesia is well described in animal studies
but the occurrence in patients is still under debate [31].
Animal studies suggest that remifentanil influences the
N-methyl-D-aspartate (NDMA) currents by affecting opioid
receptors [32,33]. Modulation of these NDMA currents
could lead to central sensitization and consequently
possibly to chronic postoperative pain.
Ideally, the study design should be double blind and
contain no other opioid besides remifentanil. As a study
arm without opioids during surgery is obviously uneth-
ical, fentanyl was selected for the other arm. The current
design, where intermittent fentanyl at predetermined
times is combined with continuous propofol as the basis
for standardized Total Intravenous Anesthesia (TIVA) in
both arms, is based on the design of a previous study in-
vestigating risk factors for chronic thoracic pain in our
hospital [15]. With one arm randomized to an additional
remifentanil infusion and one arm randomized to add-
itional intermittent fentanyl as needed, these two study
groups can both be considered the standard of care in
our hospital. Given the familiarity with the two study
arms, we do not expect unintentional effects from the
nonblinding of anesthesiologists and ward nurses. It is
emphasized that the patient is kept blinded for the treat-
ment group, which is of particular relevance since it is
the patient who determines the primary endpoint, that
is, chronic thoracic pain one year after surgery. Another
potential design that was considered was a group receiving
remifentanil only with another group receiving fentanyl
only. While the remifentanil-only group, in particular, can-
not be considered a standard of care treatment in our
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used in a previous nonrandomized study, a difference in
the prevalence of chronic thoracic pain was detected [15].
In the current study, all patients will be evaluated for
their sensory detection and pain thresholds using QST
preoperatively, 3 days and 1 year after surgery. This ran-
domized trial in which chronic thoracic pain after car-
diac surgery is studied in the remifentanil and control
arm is not only an opportunity to investigate the influ-
ence of remifentanil on sensory thresholds, but also to
explore the influence of cardiac surgery and chronic pain
on sensory modalities. Ideally, for this purpose, a pain
battery with more than one stimulus (for example, elec-
tricity and pressure) should be used; however, in our
opinion, use of a large number of pain thresholds mea-
surements is not feasible in patients prior to and 3 days
after invasive cardiac surgery.
The results of this randomized trial may be used to
optimize intraoperative analgesia techniques and thereby
improve the quality of life of patients after cardiac surgery.
Trial status
The trial is currently enrolling patients. To date, 90% of
the patients have been enrolled in the study. The ex-
pected average enrollment rate is three to five patients
every week. Data collection will stop one year after the
last patient is included.
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